The assay leverages the same powerful technology as prior versions, detecting MRD by reading the full immune receptor sequence of the malignant B cells rather than relying on individual point ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma ...

Darzalex addition to VRd improved MRD negativity and PFS in transplant-ineligible multiple myeloma patients. The CEPHEUS trial showed a 50% increase in MRD negativity with Darzalex, consistent across ...

Over the past decade, minimal residual disease (MRD) has emerged as a crucial biomarker in multiple myeloma (MM) clinical trials, with MRD-negative status strongly linked to better clinical ...

"We found that this induction induced exceptionally high response and minimal residual disease (MRD) negativity rates," said first author Aurore Perrot, MD, PhD, an associate professor of ...

Don't wait for MRD negativity if someone's having toxicities but the absence of that, I do think it's reasonable, based on the data from the master study showing that in the absence of 2 or more ...

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).

However, as all of the Metisse replicas, it is officially licensed as a 1967 model like McQueen's own bike. Photo: Collecting Cars The bike is designed for racing and is currently set up for ...

New data have come forward pointing to a link between achieving undetectable minimal residual disease (MRD) and improved treatment outcomes in multiple myeloma. The FDA appears receptive to the ...